HAS, the body responsible for making drug reimbursement decisions in France, has said that MSD’s oral antiviral, Lagevrio (molnupiravir), should not be used in the treatment of COVID-19 before it has been formally approved.
Making Lagevrio available might mean “a lost opportunity” for patients to be treated with Roche’s Ronapreve
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?